ArticleFrontiers in oncology2025
Global basal cell carcinoma in 55+ population: 1990- 2021 burden、risk-factor trends and 2050 forecast.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Ultrasound to Histopathology: Agreement Analysis and Depth Correction Model for Basal Cell Carcinoma Using a Portable 20 MHz High-Frequency Ultrasound Device.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study map the 1990-2021 basal-cell carcinoma burden in people ≥55 years worldwide, pinpoint key risk drivers, and offer concise intervention guidance for elder-focused prevention. Methods: We focused on adults aged ≥55 years because this group shows the highest basal-cell carcinoma (BCC) frequency and matches the Global Burden of Disease (GBD) age strata. Incidence and disability-adjusted life-year (DALY) counts for 1990-2021 were downloaded from the Global Health Data Exchange. After direct age-standardisation, we plotted global, regional and national rates, generated world maps, computed annual percent change (APC) and contrasted 1990 versus 2021 distributions-all with R 4.2.1. A Bayesian hierarchical model then projected the 2050 burden. Results: 1990-2021, Among adults ≥55 years, global basal-cell carcinoma incidence rose and then plateaued, while DALYs climbed before edging downward. The steepest gains in both age-standardized incidence and DALY rates occurred in high-income North America. Men consistently outpaced women across all metrics. The USA, Brazil and China recorded the largest absolute caseloads, yet the USA always posted the highest incidence rate and Nepal the lowest. Overall, the BCC burden has expanded over the past three decades. Conclusion: Over the last three decades, both new cases and the overall toll of basal-cell carcinoma among older adults have risen worldwide, fueled by expanding and aging populations, greater ultraviolet exposure, and better case detection. Looking forward, vigorous sun-protection education and unified UV-shielding measures are essential to curb incidence and ease the growing burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.